100-mg Scored Tablets and
300-mg Scored Tablets
ZYLOPRIM is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allopurinol and each scored peach tablet contains 300 mg allopurinol.
THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA.
ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS).
ZYLOPRIM is indicated in:
- the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
- the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present.
- the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Media Articles Related to Zyloprim (Allopurinol)
Less than half of gout patients reach recommended treatment goal following treatment with allopurinol
Source: Gout News From Medical News Today [2013.10.31]
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout.
UK rates of gout soaring, but treatment remains poor
Source: Gout News From Medical News Today [2014.01.16]
UK rates of gout have soared since the late1990s, with one in every 40 people now affected by the condition - the highest in Europe - but treatment remains as poor now as it was then, reveals research published online in the Annals of the Rheumatic Diseases.
Gout runs strongly in families, suggests large-scale study
Source: Gout News From Medical News Today [2013.12.03]
Researchers from the UK's University of Nottingham and colleagues conducted a new study of the population of Taiwan, where there is a high rate of gout, and found that the condition clusters in families.
Gout (Gouty Arthritis)
Source: MedicineNet Bunions Specialty [2013.12.03]
Title: Gout (Gouty Arthritis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/3/2013 7:21:42 PM
Risk of heart attack and stroke doubles for patients with gout
Source: Gout News From Medical News Today [2013.10.03]
New research published in Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.The findings showed that gout patients are twice as likely to suffer a heart attack or stroke as those without gout.
Published Studies Related to Zyloprim (Allopurinol)
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. [2011.08.16]
OBJECTIVES: The aim of this study was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and endothelial function in subjects with stable coronary artery disease (CAD). BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, prolongs the time to chest pain during exercise in angina. We sought to ascertain whether allopurinol also improves endothelial dysfunction in optimally treated CAD patients, because such an effect might be of value to reduce future cardiovascular mortality. The mechanism of the anti-ischemic effect of allopurinol could be related to its reducing xanthine oxidase-induced OS, and our second aim was to see whether allopurinol really does reduce vascular tissue OS in CAD patients... CONCLUSIONS: Our study demonstrates that, in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascular tissue OS and improves 3 different measures of vascular/endothelial dysfunction. The former effect on OS might underpin the anti-ischemic effect of allopurinol in CAD. Both effects (on OS and endothelial dysfunction) increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality in CAD, over and above existing optimum therapy. (Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina; ISRCTN15253766). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. [2011.07]
Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD.Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. [2011.07]
OBJECTIVE: This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1beta monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment... CONCLUSIONS: Single canakinumab doses >/=50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg.
Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. [2011.06]
OBJECTIVES: Endothelial dysfunction is a well known risk factor for atherosclerosis. Uric acid levels are associated with endothelial dysfunction and atherosclerosis even if in physiological range. Xanthine oxidase inhibition with allopurinol decreases uric acid levels and oxidative stress and improves endothelial function. We have investigated the effect of high-dose and long-term allopurinol therapy on endothelial function in diabetic normotensive patients... CONCLUSION: Long-term and high-dose allopurinol therapy significantly improved endothelial function in diabetic normotensive patients. In addition, allopurinol therapy contributes to the lower HbA1c levels.
Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. [2011.04]
CONCLUSIONS: Allopurinol does not produce additional antihypertensive effects in patients with treated arterial hypertension. Allopurinol increases aortic compliance independently of ACE-I or thiazide-based, antihypertensive therapy. However, this effect is significantly dependent on the initial PWV in the aorta and on SBP changes during allopurinol therapy.
Clinical Trials Related to Zyloprim (Allopurinol)
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode [Recruiting]
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo,
as add-on to mood stabilizers and/or antipsychotic in the treatment of patients with bipolar
disorder, in a manic episode.
Allopurinol Combination Study [Recruiting]
To compare the proportion of subjects whose serum urate (sUA) levels are < 6. 0 mg/dL
following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to
allopurinol alone in subjects with documented inadequate hypouricemic response with standard
doses of allopurinol.
A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient [Recruiting]
To know the blood level of allopurinol in chronic kidney disease (CKD) patient.
Allopurinol in Acute Coronary Syndrome [Recruiting]
Allopurinol is a drug commonly used to treat gout. However recent studies have shown it has
the potential to help improve oxygen supply to heart muscle. In this study the Investigators
aim to find out if allopurinol slows down the onset of angina symptoms, as seen by a doctor
on a tracing of the heart (ECG- electrocardiogram), for patients who have been diagnosed
with heart disease, when exercising on a treadmill. The Investigators are also are trying to
figure out the best dose of allopurinol to use and to see how quickly it begins working. To
do this the investigators will recruit patients with angina, exercise them on a treadmill
after giving different doses of allopurinol and see if there is an improvement in their time
to bring on angina symptoms and signs. Patients recruited to this trial will receive three
different treatment regimes over a six week period. Each treatment regime will last for one
week with a one week rest period between each regime. This will involve up to eleven visits
to Ninewells Medical School, Dundee for testing.
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies [Recruiting]
This randomized phase II trial studies how well giving rasburicase together with allopurinol
works in treating patients with hematologic malignancies. Rasburicase may reduce the level
of uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. It is not yet known which dose of rasburicase is more
effective in treating hematologic malignancies when given together with or without